A Phase 2, 12-week, Adaptive, Open Label, Sequential Cohort Trial To Evaluate The Efficacy, Safety, Tolerability And Pharmacokinetics Of Pf-06730512 Following Multiple Doses In Adult Subjects With Primary Focal Segmental Glomerulosclerosis (Fsgs)

Trial Profile

A Phase 2, 12-week, Adaptive, Open Label, Sequential Cohort Trial To Evaluate The Efficacy, Safety, Tolerability And Pharmacokinetics Of Pf-06730512 Following Multiple Doses In Adult Subjects With Primary Focal Segmental Glomerulosclerosis (Fsgs)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 19 Aug 2018

At a glance

  • Drugs PF-06730512 (Primary)
  • Indications Focal segmental glomerulosclerosis
  • Focus Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 27 Jul 2018 Planned End Date changed from 12 Apr 2021 to 7 May 2021.
    • 27 Jul 2018 Planned primary completion date changed from 12 Apr 2021 to 7 May 2021.
    • 02 Jul 2018 Planned End Date changed from 16 Mar 2021 to 12 Apr 2021.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top